Skip to content

Pharmacokinetic/Pharmacodynamic Model of Propofol in Children

Pharmacokinetic/Pharmacodynamic Model of Propofol in Children

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02544854
Enrollment
40
Registered
2015-09-09
Start date
2015-09-30
Completion date
2016-12-31
Last updated
2016-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Keywords

Pharmacokinetics, pharmacodynamics, propofol, pediatrics

Brief summary

By measuring plasmatic concentration of propofol at different intervals during surgery of children aged 1 to 12 years old and measuring Bispectral Index (BIS) as a surrogate for cerebral activity, the investigators aim to create a pharmacokinetic/pharmacodynamic model of propofol for children.

Detailed description

Propofol is an intravenous anesthetic capable of providing a safe general anesthesia, free from many of the adverse effects associated with inhalation anesthetics (postoperative nausea and vomiting, agitation on awakening, seizures and trigger malignant hyperthermia crisis) and widely used in adults, but even less so in children. This is due to the fact that its pharmacological characteristics have not been clarified at all in the pediatric population. The physiological maturation of different systems in children, as well as changes in body composition and metabolism may determine significant changes in the pharmacokinetics (distribution volumes and clearance) of children. Moreover, within the same age group, variations across different individuals may make even less predictable the pharmacokinetic models currently in use. Indeed, previous work in our group based on these models have shown that propofol dosage required by children to induce general anesthesia is inversely proportional to the age, which could be explained by biases in these models, different sensitivity to propofol at different ages and sizes, etc. The effect of propofol in the brain is described by its pharmacodynamics, but in children this is still in debate. Using a brain activity monitor (BIS), the effect of propofol at the central nervous system can be analyzed under a model of nonlinear mixed effects (NONMEM) and establish the time to peak effect to characterize in detail the pharmacodynamics of this drug. Integrating pharmacokinetic and pharmacodynamic data, a pharmacokinetic/pharmacodynamic (PK/PD) model for the pediatric population can be derived. The aim of this paper is to describe the first PK / PD model of propofol in children, valid for different ages and to analyze them in the context of different body composition parameters. The importance of this study is that its results will publish the missing link in the pediatric pharmacology of propofol, which will encourage more research and more widespread use of this technique in the pediatric population.

Interventions

DRUGPropofol

Propofol infusion will be started after inhalational induction by manual infusion by the following scheme: 1. First 15 minutes: 15 mg/kg/min 2. 16 to 30 minutes: 13 mg/kg/min 3. 31 to 60 minutes: 11 mg/kg/min 4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50. Venous sampling for plasmatic levels of propofol measuring will be made at the following moments: 1. 5, 15 and 25 minutes of starting infusion, 2. 1, 3, 5, 7, 9 and 12 minutes of bolus and, 3. 5, 25, 60 and 120 minutes of infusion ended.

Sponsors

Pontificia Universidad Catolica de Chile
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* Children aged 1 year through 11 years 11 months and 29 days old. * American Society of Anesthesiology (ASA) score 1 or 2. * Elective surgery of more than 1 hour of expected duration. * Written informed consent signed by parents or legal guardians. * Oral and written consent in children aged over 7 years old.

Exclusion criteria

* Known allergies to study drugs. * Use of any medication acting on central nervous system in the last 24 hours previous to surgery. * Chronic cardiac, renal, hepatic or neurologic disease that determines abnormal function. * Difficult airway (predicted or known). * Use of neuraxial anesthesia.

Design outcomes

Primary

MeasureTime frameDescription
Propofol plasmatic levelsFrom start of infusion: 5 min, 15 min, 45 min; from bolus 0 min, 1 min, 3 min, 5 min, 10 min; after infusion 30 min, 60 min, 120 min, 360 minMeasured by high pressure liquid chromatography

Secondary

MeasureTime frameDescription
HemodynamicsEntering operating room up to end of anesthesiaHeart rate and arterial pressure
Propofol total doseStart of propofol infusion until it endsMeasured in milligrams
Sevoflurane total doseStart of inhalational induction to zero end tidal concentration
Pulse oximetryEntering operating room up to end of anesthesia
BISEntering operating room up to end of anesthesiaDepth of anesthesia will be recorded with BIS monitor

Countries

Chile

Contacts

Primary ContactRicardo Fuentes, MD
rfuente@med.puc.cl56-9-77648344

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026